NCT02215967View on ClinicalTrials.gov

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 12, 2014

Primary Completion Date

April 25, 2019

Study Completion Date

August 15, 2019

Conditions
Myeloma, Plasma-CellMyeloma-Multiple
Interventions
DRUG

Cyclophosphamide

300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

DRUG

Fludarabine

30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3

BIOLOGICAL

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells

0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02215967 - Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | Biotech Hunter | Biotech Hunter